You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 909.00p
Change Today:
-47.00p
Market Cap:
783.33m
Sector:
Pharmaceuticals & Biotechnology

Oxford Biomedica signs deal with Beam Therapeutics

By Josh White

Date: Monday 03 Aug 2020

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.
The FTSE 250 company said the agreement granted Beam a non-exclusive license to Oxford Biomedica's 'LentiVector' platform, for its application in "next-generation" CAR-T programmes in oncology, and put in place a three-year cinical supply agreement.

Under the terms of the deal, Oxford Biomedica would receive an undisclosed upfront payment, as well as payments related to development and manufacturing of lentiviral vectors for use in clinical trials, and certain development and regulatory milestones for products sold by Beam that use the LentiVector platform, and an undisclosed royalty on the net sales of products sold by Beam that utilise the LentiVector platform.

Oxford Biomedica said it was currently working on one pre-clinical programme with Beam, with the agreement allowing for the parties to initiate additional projects in the future.

"Beam Therapeutics is one of the leading next-generation CAR-T developers who deploy a wide range of innovative technologies to bring innovative CAR-T products into development," said chief executive officer John Dawson.

"We are proud to be working with a leader in the field of gene editing technologies, including base editing, and this provides us another valuable opportunity for our LentiVector platform to support innovative product development of CAR-T products.

"This is our third announced partnership with leaders in the CAR-T field, building on our longstanding partnership with Novartis and our more recently announced partnership with Bristol Myers Squibb earlier this year. We look forward to supporting the next generation CAR-T programmes at Beam."

At 0825 BST, shares in Oxford Biomedica were up 0.61% at 822p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 909.00p
Change Today -47.00p
52 Week High 1,634.00p
52 Week Low 905.00p
Volume 166,710
Shares Issued 86.18m
Market Cap 783.33m
Beta 0.03

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Price Chg 6m
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 5
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 21-Jan-2022

Time Volume / Share Price
16:37 15,000 @ 911.95p
16:35 30,499 @ 909.00p
16:29 91 @ 916.00p
16:29 8 @ 916.00p
16:29 8 @ 913.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter